NRx Pharmaceuticals and neurocare Group Partner to Create Nationwide Neuroplastic Therapy Network for Depression and PTSD
核心洞察
NRx Pharmaceuticals and neurocare Group AG (搜索) announced a partnership to create a nationwide network of clinics offering integrated neuroplastic therapy for depression (搜索), PTSD (搜索), and other mental health disorders.
The partnership will leverage 400+ existing Apollo TMS devices and combine transcranial magnetic stimulation with ketamine therapy, hyperbaric oxygen, and psychotherapy to achieve high remission rates.
Recent scientific publications demonstrate that TMS integration with neuroplastic drugs achieved 87% response rates and 72% remission in treatment-resistant depression (搜索) patients.
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) and neurocare Group AG (搜索) announced a strategic partnership to establish a nationwide network of clinics delivering integrated neuroplastic therapy for depression (搜索), post-traumatic stress disorder (PTSD (搜索)), and other serious mental health conditions. The collaboration aims to address the fragmented landscape of neuroplastic treatments by combining transcranial magnetic stimulation (TMS) technology with neuroplastic drug therapies.
Integrated Treatment Approach Shows Promising Results
The partnership builds on pilot programs demonstrating high success rates when combining TMS with ketamine and other neuroplastic drugs, along with hyperbaric oxygen therapy and supportive psychotherapy. These integrated approaches have achieved significant remission rates among first responders with PTSD (搜索) and depression (搜索).
Recent scientific publications have shown that integrating TMS with neuroplastic drugs achieved unprecedented response rates of 87% and remission rates of 72% in patients with treatment-resistant depression (搜索). While these results are early and require further study, they represent a significant advancement in treating challenging mental health conditions.
Nationwide Network Expansion Strategy
The partnership will integrate existing neurocare clinics with HOPE Therapeutics (搜索) clinics and engage the already-installed base of more than 400 Apollo TMS machines nationwide. The collaboration leverages neurocare's rapidly-growing clinic network of 20 facilities in the US, combined with their extensive TMS device installations.
By the end of 2026, the partners aim to offer innovative neuroplastic therapy within driving distance of any home in the United States. This ambitious expansion targets CNS diseases that afflict more than 50 million people in the US and 500 million worldwide.
Technology Platform and Clinical Infrastructure
neurocare Group AG (搜索) has developed a comprehensive platform for neuroplastic therapy that includes the Apollo TMS device with over 400 US installations. The platform encompasses EEG-guided TMS therapy, neurofeedback protocols, sleep analysis devices, and neurocare OS—a patient and data management system.
The neurocare Academy provides online and in-person medical education, training and certifying physicians, therapists, and technologists in TMS and other neuroplastic therapies. This educational component addresses the need for standardized training protocols across the expanding network.
Drug Development Pipeline Integration
NRx Pharmaceuticals brings a decade of experience in developing neuroplastic drugs to the partnership. The company is advancing NRX-100 (preservative-free intravenous ketamine) under an ANDA filed with the FDA, with an expected decision date of July 2026. The drug has received Fast Track Designation for treating suicidal ideation in depression (搜索), including bipolar depression (搜索).
NRX-101, an oral combination of D-cycloserine and lurasidone, has been awarded Breakthrough Therapy Designation for treating suicidal bipolar depression (搜索). The partners are exploring joint regulatory paths including clinical trials to address bipolar depression, autism (搜索), and traumatic brain injury (搜索).
Focus on High-Need Populations
The initial focus targets first responders, active duty military personnel, and veterans—populations with urgent needs for effective, integrated mental health treatments. HOPE Therapeutics (搜索) clinics already maintain contracts with the VA Community Cares Program and the Department of Defense TRICARE program.
"For too long, the approach to neuroplastic therapy for depression (搜索) and PTSD (搜索) has been highly fragmented, with some clinics offering ketamine, some offering TMS, some offering hyperbaric therapy but almost no fully integrated solutions," said Dr. Jonathan Javitt, Founder, Chairman, and CEO of NRx Pharmaceuticals and HOPE Therapeutics (搜索).
Market Position and Financial Outlook
neurocare Group AG (搜索), founded by former Fresenius leaders, has grown to annual sales exceeding €35 million in 2025 and expects to exceed €50 million in 2026. The company operates 40 clinics across the US, UK, Netherlands, and Australia, with over 400 customer sites in the US alone.
Tom Mechtersheimer, neurocare's Founder & CEO, emphasized the alignment between the companies: "We believe that the pipeline of NRx and our platform complement one another as we seek to offer patients and payers a fully integrated solution that maximizes remission from severe depression (搜索) and PTSD (搜索) today and additional debilitating CNS conditions in the future."
The partnership represents an attempt to create an accountable care model similar to successful approaches in renal care delivery, offering payers a single point of contact for comprehensive neuroplastic therapy services.